Companies like Exxon Mobil, Wyeth and Pfizer--which tend to rely on single patents for their products--are worried the law would make it easier for patents to be challenged and thus would dry up funding for research.
Rose, intellectual property litigator with Bradley Arant Boult Cummings, a law firm in Nashville, the issue may not be entirely as cut and dry as some think.